Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates — Negative
LUCD Zacks Investment Research — November 12, 2025Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.
Countdown to Aramark (ARMK) Q4 Earnings: Wall Street Forecasts for Key Metrics — Neutral
ARMK Zacks Investment Research — November 12, 2025Evaluate the expected performance of Aramark (ARMK) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
UNIVERSAL INSURANCE HOLDINGS INC (UVE) Hits Fresh High: Is There Still Room to Run? — Positive
UVE Zacks Investment Research — November 12, 2025Universal Insurance (UVE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run? — Positive
BDTX Zacks Investment Research — November 12, 2025Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Crexendo Inc. (CXDO) Soars to 52-Week High, Time to Cash Out? — Positive
CXDO Zacks Investment Research — November 12, 2025Crexendo (CXDO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LiveOne (LVO) Reports Q2 Loss, Beats Revenue Estimates — Neutral
LVO Zacks Investment Research — November 12, 2025LiveOne (LVO) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.2 per share a year ago.
Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors — Positive
CCCC CWST ESPR INSP MNDY SITM Seeking Alpha — November 12, 2025Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide range of electronics. The greatest detractor from Fund performance for the quarter was Monday.com Ltd.
Baidu Q3 Earnings Preview: AI Cloud Strength Is Still Ignored By The Market — Neutral
BIDU Seeking Alpha — November 12, 2025Baidu's online marketing business is facing a double whammy, with a 15% Q2 decline and a bleak Q3 guide. This is the main story the market is focused on. However, the market is mispricing Baidu as a declining ad business, completely ignoring its rapid and successful transformation into a full-stack AI hyperscaler. Baidu's in-house chip development mirrors Google's and Amazon's, de-risks the business geopolitically, and is already winning billion-RMB contracts.
BlackRock TCP Capital: Earnings Continue To Decline For Q3 — Neutral
BLK Seeking Alpha — November 12, 2025BlackRock TCP Capital continues to underperform, with a 34.2% share price decline and a 22.2% total return loss over the past year. Despite a high 17.5% dividend yield, TCPC's net investment income and portfolio activity are declining, raising concerns about long-term sustainability. TCPC trades at a historically large 34.56% discount to NAV, reflecting portfolio weakness and negative sentiment in the debt markets.
Nuwellis, Inc. (NUWE) Q3 2025 Earnings Call Prepared Remarks Transcript — Neutral
NUWE Seeking Alpha — November 12, 2025Nuwellis, Inc. ( NUWE ) Q3 2025 Earnings Call November 12, 2025 9:00 AM EST Company Participants Leah McMullen - Director of Communications John Erb - Interim CFO, Interim Principal Financial & Accounting Officer, CEO, President and Chairman Lynn Blake Presentation Operator Good day, everyone, and welcome to today's Nuwellis Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, today's call will be recorded, and I will be standing by should you need any assistance.
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript — Neutral
ACXP Seeking Alpha — November 12, 2025Acurx Pharmaceuticals, Inc. ( ACXP ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, Corporate Secretary & Director Conference Call Participants Matthew Keller - H.C. Wainwright & Co, LLC, Research Division James Molloy - Alliance Global Partners, Research Division Presentation Operator Greetings, and welcome to the Acurx Pharmaceuticals Third Quarter 2025 Conference Call and Business Update.
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates — Negative
ATXS Zacks Investment Research — November 12, 2025Astria Therapeutics, Inc. (ATXS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.42 per share a year ago.
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm — Neutral
TVRD GlobeNewsWire — November 12, 2025LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tvardi Therapeutics, Inc. (“Tvardi” or “the Company”) (NASDAQ: TVRD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Geospace Paradox: A Transformation Priced For Perfection — Positive
GEOS Seeking Alpha — November 12, 2025Geospace Technologies (GEOS) has transformed from a chronic underperformer to a recent stock market winner through strategic diversification and high-profile contracts. GEOS's expansion into smart water infrastructure and border security, alongside its core energy business, has driven strong revenue growth and improved operational efficiency. Despite diversification, GEOS still struggles to achieve sustainable profitability, with only intermittent positive net income and a history of volatile earnings.
Microsoft Corporation delivered strong Q1 results, with top-line growth accelerating and Azure driving robust performance. MSFT's Intelligent Cloud segment saw 28% YoY growth, with Azure and cloud services up 40%, justifying heavy CAPEX investment. Despite slightly mixed Q2 guidance and some margin pressure, demand for AI compute remains strong, supporting continued growth.
Gold Price Outlook – Gold Continues to Consolidate on Wednesday — Negative
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL UGL FXEmpire — November 12, 2025Gold remains choppy and range bound as traders assess the impact of the US dollar and global rate expectations. Key levels between $4,150 and $4,200 define near-term action, with the 50-day EMA serving as critical support for this trend overall.
Sniffing out rodents, one paw at a time: Orkin Canada launches K9 detection service in Vancouver — Neutral
ROL GlobeNewsWire — November 12, 2025VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Rodents may be experts at staying hidden, but in Metro Vancouver, there's a new sleuth on the case. Orkin Canada has launched its professional K9 rodent detection service in the region, using a specially trained rescue dog, Puzzle, to sniff out live rodent activity with unmatched accuracy.
The Nuclear Energy Renaissance: Investment Opportunities for Advisors — Positive
NUKZ ETF Trends — November 12, 2025The nuclear energy sector is experiencing a powerful revival, driven by macroeconomic shifts and technological innovation. For financial advisors and investors, understanding these trends is key to identifying investment opportunities as the nuclear energy landscape evolves.
American Axle Q3 Earnings Surpass Estimates, Decrease Y/Y — Positive
AXL Zacks Investment Research — November 12, 2025AXL posts Q3 earnings and revenue beats, trims revenues and adjusted free cash flow 2025 outlook.
Here is What to Know Beyond Why Zoom Communications, Inc. (ZM) is a Trending Stock — Positive
ZM Zacks Investment Research — November 12, 2025Zacks.com users have recently been watching Zoom (ZM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.